Capitalizing on its rising stock price driven by avian flu fears, Novavax Inc. is bringing in $18 million through a public offering to support clinical development. (BioWorld Today)
Capitalizing on its rising stock price driven by avian flu fears, Novavax Inc. is bringing in $18 million through a public offering to support clinical development. (BioWorld Today)